Published in Angiogenesis Weekly, July 9th, 2010
"Twenty-nine heavily pretreated patients [median 3 [0-7] ] were enrolled on five dose levels. No additive or cumulative toxicity was observed, and grade III nonhematological toxicity was rare. Neutropenia was the most common hematologic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Angiogenesis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.